Table 3.
Change1 in seropositive OD ratios between baseline (BL) and follow-up (FU)2 for BL seropositive cases
| Change1 in OD Ratio | HPV-16 E6 N = 22 | HPV-16 E7 n = 20 |
|---|---|---|
| n (%) | n (%) | |
| BL to FU1 | ||
| No decrease | 8 (36.6) | 10 (50.0) |
| Decrease | 14 (63.4) | 10 (50.0) |
| p-value3 | 0.10 | 0.50 |
| BL to FU2 | ||
| No decrease | 3 (25.0) | 4 (36.4) |
| Decrease | 9 (75.0) | 7 (63.6) |
| p-value3 | 0.04 | 0.19 |
| BL to last FU | ||
| No decrease | 6 (27.3) | 7 (35.0) |
| Decrease | 16 (72.7) | 13 (65.0) |
| p-value3 | 0.02 | 0.09 |
1Based on ≥ 2-fold titration change using the last titration at each follow-up. 2FU1 = follow-up 1, FU2 = follow-up 2, FU = last follow-up, 3One-sided p-values for the binomial test that the proportion of patients who decreased was > 0.50.